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S1. General Experimental Procedures
Optical rotations were recorded on a Perkin-Elmer 341 polarimeter (Villebon-sur-Yvette, France). IR spectra were recorded on a FT-IR Shimadzu 8400 S spectrometer (Noisiel, France). UV spectra were recorded on a UVIKON 930 spectrometer (Kontron, France). Mass spectra were recorded on an API Q-STAR PULSAR I of Applied Biosystems (Concord, ON, Canada). NMR spectra were obtained on either a Bruker Avance 400 or 600 spectrometer (Wissenburg, France) using standard pulse sequences. The acquisition of HMBC spectra was optimized for either 7 or 8.3 Hz. Column chromatography (CC) purifications were performed using silica gel (200~400 mesh; Merck, Darmstadt, Germany) and Sephadex LH-20 (Amersham Pharmacia, Uppsala, Sweden). Fractions were analyzed by TLC using aluminum-backed sheets (Silica gel 60 F254) and visualized under UV (254 nm) and Lieberman spray reagent. Preparative TLC used glass plate coated with silica gel 60 F254, 0.25 mm thick (Merck, Darmstadt, Germany). Flash chromatography was carried out on Buchi C-615 pump system (Rungis, France). Analytical and semi-preparative reverse-phase (Gemini C6-phenyl, Luna RP18 and HILIC, Phenomenex, Le Pecq, France) columns were performed with an Alliance HPLC apparatus (model 2695, Waters, Saint-Quentin en Yvelines, France), equipped with a
